XML 39 R18.htm IDEA: XBRL DOCUMENT v3.23.1
Segments of Business and Geographic Areas
 3 Months Ended
Apr. 02, 2023
Segment Reporting [Abstract]  
Segments of Business and Geographic Areas SEGMENTS OF BUSINESS AND GEOGRAPHIC AREAS
SALES BY SEGMENT OF BUSINESS
 Fiscal First Quarter Ended
(Dollars in Millions)April 2,
2023		April 3,
2022		Percent
Change
CONSUMER HEALTH   
OTC
     U.S.$745 670 11.0 %
     International897 791 13.5 
     Worldwide 1,642 1,461 12.4 
Skin Health/Beauty
     U.S.617 544 13.4 
     International493 468 5.3 
     Worldwide 1,110 1,012 9.7 
Oral Care
     U.S.159 143 11.6 
     International202 223 (9.6)
     Worldwide 361 366 (1.3)
Baby Care
     U.S.96 85 13.0 
     International263 270 (2.8)
     Worldwide 359 355 1.0 
Women’s Health
     U.S.3 3 1.8 
     International214 224 (4.9)
     Worldwide 217 228 (4.8)
Wound Care/Other
     U.S.115 112 2.6 
     International49 52 (6.0)
     Worldwide 164 164 (0.1)
TOTAL CONSUMER HEALTH
     U.S.1,735 1,557 11.4 
     International2,117 2,029 4.4 
     Worldwide 3,852 3,586 7.4 
PHARMACEUTICAL
Immunology
     U.S.2,448 2,501 (2.1)
     International1,664 1,617 2.9 
     Worldwide 4,112 4,119 (0.2)
     REMICADE
     U.S.276 358 (22.8)
     U.S. Exports41 80 (48.8)
     International170 225 (24.4)
     Worldwide 487 663 (26.5)
     SIMPONI / SIMPONI ARIA
     U.S.271 287 (5.6)
     International266 283 (6.1)
     Worldwide 537 571 (5.8)
     STELARA
     U.S.1,451 1,379 5.2 
     International993 909 9.3 
     Worldwide 2,444 2,288 6.8 
     TREMFYA
     U.S.406 391 3.9 
     International234 199 17.3 
     Worldwide 640 590 8.4 
     OTHER IMMUNOLOGY
     U.S.3 6 (51.2)
     International00— 
     Worldwide 3 6 (51.3)
Infectious Diseases
     U.S.392 461 (14.9)
     International1,193 836 42.8 
     Worldwide 1,586 1,297 22.3 
     COVID-19 VACCINE
     U.S.075 *
     International747 382 95.6 
     Worldwide747 457 63.4 
     EDURANT / rilpivirine
     U.S.9 9 (1.4)
     International271 239 13.4 
     Worldwide 280 248 12.8 
      PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA
     U.S.378 369 2.5 
     International99 132 (25.2)
     Worldwide 477 501 (4.8)
     OTHER INFECTIOUS DISEASES
     U.S.5 8 (33.1)
     International77 83 (7.6)
     Worldwide 82 91 (9.8)
Neuroscience
     U.S.978 843 16.0 
     International826 898 (8.1)
     Worldwide 1,804 1,741 3.6 
     CONCERTA / methylphenidate
     U.S.70 35 *
     International136 122 11.4 
     Worldwide 206 157 31.4 
     INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA
     U.S.713 661 7.9 
     International331 387 (14.6)
     Worldwide 1,044 1,048 (0.4)
     SPRAVATO
     U.S.111 61 82.4 
     International20 9 *
     Worldwide 131 70 86.9 
     OTHER NEUROSCIENCE(1)
     U.S.84 86 (3.5)
     International339 380 (10.7)
     Worldwide 423 467 (9.4)
Oncology
     U.S.1,889 1,582 19.4 
     International2,223 2,369 (6.1)
     Worldwide 4,112 3,950 4.1 
      CARVYKTI
     U.S.70 — *
     International2 — *
     Worldwide72 — *
     DARZALEX
     U.S.1,191 953 25.0 
     International1,072 903 18.8 
     Worldwide 2,264 1,856 22.0 
     ERLEADA
     U.S.249 206 21.2 
     International293 194 50.9 
     Worldwide 542 400 35.6 
     IMBRUVICA
     U.S.270 370 (27.1)
     International557 668 (16.6)
     Worldwide 827 1,038 (20.3)
     ZYTIGA / abiraterone acetate
     U.S.16 19 (14.0)
     International229 520 (56.0)
     Worldwide 245 539 (54.5)
     OTHER ONCOLOGY
     U.S.92 34 *
     International70 84 (17.2)
     Worldwide 162 118 37.4 
Pulmonary Hypertension
     U.S.600 572 4.9 
     International272 279 (2.7)
     Worldwide 872 852 2.4 
     OPSUMIT
     U.S.273 273 (0.1)
     International167 170 (1.6)
     Worldwide 440 443 (0.7)
     UPTRAVI
     U.S.304 269 13.1 
     International58 56 3.3 
     Worldwide 362 325 11.4 
     OTHER PULMONARY HYPERTENSION
     U.S.23 30 (22.4)
     International47 53 (12.6)
     Worldwide 70 83 (16.1)
Cardiovascular / Metabolism / Other
     U.S.715 672 6.3 
     International212 238 (10.8)
     Worldwide 927 910 1.8 
     XARELTO
     U.S.578 508 13.7 
     International— — — 
     Worldwide 578 508 13.7 
     OTHER(2)
     U.S.137 164 (16.7)
     International212 238 (10.8)
     Worldwide 349 402 (13.2)
TOTAL PHARMACEUTICAL  
     U.S.7,023 6,632 5.9 
     International6,390 6,237 2.4 
     Worldwide 13,413 12,869 4.2 
MEDTECH
Interventional Solutions
     U.S.863 494 74.5 
     International640 597 7.1 
     Worldwide 1,503 1,092 37.6 
     ELECTROPHYSIOLOGY
     U.S.571 470 21.4 
     International522 532 (1.8)
     Worldwide1,092 1,002 9.1 
     ABIOMED(3)
     U.S.264 — *
     International60 — *
     Worldwide324 — *
     OTHER INTERVENTIONAL SOLUTIONS
     U.S.28 24 17.4 
     International58 65 (11.7)
     Worldwide87 90 (3.9)
Orthopaedics
     U.S.1,363 1,289 5.8 
     International881 899 (2.0)
     Worldwide 2,245 2,188 2.6 
     HIPS
     U.S.241 225 7.3 
     International149 164 (9.0)
     Worldwide 390 389 0.4 
     KNEES
     U.S.226 201 12.4 
     International142 138 3.4 
     Worldwide 368 339 8.7 
     TRAUMA
     U.S.491 475 3.2 
     International267 273 (2.4)
     Worldwide 757 748 1.2 
     SPINE, SPORTS & OTHER
     U.S.406 387 4.7 
     International323 324 (0.3)
     Worldwide 729 712 2.4 
Surgery
     U.S.975 921 5.9 
     International1,459 1,513 (3.6)
     Worldwide 2,434 2,434 0.0 
     ADVANCED
     U.S.444 417 6.5 
     International673 729 (7.6)
     Worldwide 1,118 1,146 (2.5)
     GENERAL
     U.S.531 504 5.4 
     International785 784 0.2 
     Worldwide 1,316 1,288 2.2 
Vision
     U.S.558 521 7.1 
     International743 736 0.8 
     Worldwide 1,300 1,257 3.4 
     CONTACT LENSES / OTHER
     U.S.444 400 11.1 
     International509 511 (0.3)
     Worldwide 953 910 4.7 
     SURGICAL
     U.S.114 121 (6.0)
     International233 226 3.3 
     Worldwide 347 347 0.1 
TOTAL MEDTECH  
     U.S.3,759 3,225 16.6 
     International3,722 3,746 (0.6)
     Worldwide 7,481 6,971 7.3 
WORLDWIDE   
     U.S.12,517 11,414 9.7 
     International12,229 12,012 1.8 
     Worldwide $24,746 23,426 5.6 %
*Percentage greater than 100% or not meaningful
(1) Inclusive of RISPERDAL CONSTA which was previously disclosed separately
(2) Inclusive of INVOKANA which was previously disclosed separately
(3) Acquired on December 22, 2022

EARNINGS/(LOSS) BEFORE PROVISION FOR TAXES BY SEGMENT
 Fiscal First Quarter Ended
(Dollars in Millions)April 2,
2023		April 3,
2022		Percent
Change
Consumer Health(1)
$776 686 13.1 %
Pharmaceutical(2)
4,444 3,924 13.3 
MedTech(3)
1,445 1,477 (2.2)
Segment earnings before provision for taxes6,665 6,087 9.5 
Less: Expense not allocated to segments (4)
7,102 123  
Less: Consumer Health separation costs 300 102 
Worldwide income/(loss) before tax$(737)5,862 *
*Percentage greater than 100% or not meaningful
(1) Consumer Health includes:
•Intangible amortization expense of $0.1 billion in both the fiscal first quarter of 2023 and 2022.

(2) Pharmaceutical includes:
•Intangible amortization expense of $0.7 billion and $0.8 billion in the fiscal first quarter of 2023 and 2022, respectively.
•COVID-19 Vaccine related exit costs of $0.4 billion in the fiscal first quarter of 2023.
•A restructuring related charge of $0.1 billion in the fiscal first quarter of 2023.
•In the fiscal first quarter of 2022, the Company recorded an intangible asset impairment charge of approximately $0.6 billion related to an in-process research and development asset, bermekimab (JnJ-77474462), an investigational drug for the treatment of Atopic Dermatitis (AD) and Hidradenitis Suppurativa (HS).
•Unfavorable changes in the fair value of securities in the fiscal first quarter of 2022 of $0.4 billion.

(3) MedTech includes:
•Intangible amortization expense of $0.4 billion and $0.3 billion in the fiscal first quarter of 2023 and 2022, respectively.
•A restructuring related charge of $0.1 billion in the fiscal first quarter of 2022.

(4)Amounts not allocated to segments include interest income/expense and general corporate income/expense. The fiscal first quarter of 2023 includes the incremental $6.9 billion charge related to the talc settlement proposal. See Note 11, Legal Proceedings, for additional details.

SALES BY GEOGRAPHIC AREA
 Fiscal First Quarter Ended
(Dollars in Millions)April 2, 2023April 3, 2022Percent
Change
United States$12,517 11,414 9.7 %
Europe6,332 6,024 5.1 
Western Hemisphere, excluding U.S.1,587 1,482 7.1 
Asia-Pacific, Africa4,310 4,506 (4.3)
Total$24,746 23,426 5.6 %